Document:

<PAGE>
                                                                   Exhibit 10.17

                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

      This AGREEMENT for Human Umbilical Cord Blood Processing Services (the
"Agreement"), effective December 1, 2001 (the "Effective Date") is by and
between VIACORD, INC. ("VIACORD"), a Delaware corporation and a wholly-owned
subsidiary of ViaCell, Inc., with its principal office at 131 Clarendon Street,
3rd Floor, Boston, Massachusetts 02116, and PROGENITOR CELL THERAPY, L.L.C.
("PCT"), a limited liability company organized and existing under the laws of
the state of New Jersey, with its principal office at 20 Prospect Avenue, Suite
400, Hackensack, New Jersey 07601.

                                    RECITALS

      WHEREAS, PCT operates a laboratory that processes human cells for the
treatment of human disease, including, without limitation, cellular therapy
services;

      WHEREAS, ViaCord is a private human umbilical cord blood banking company
that engages in the business of private cord blood banking, which includes
collecting blood from a newborn's umbilical cord and/or placenta immediately
after delivery, and the processing and freezing of such blood for long-term
cryogenic storage;

      WHEREAS, ViaCord desires to engage PCT to provide the services listed in
Attachment I (the "Services") pursuant to the terms of this Agreement, and PCT
desires to accept such engagement pursuant to the terms of this Agreement; and

      NOW, THEREFORE, in consideration of the premises and the mutual covenants
and other good and valuable consideration hereinafter contained, the parties
hereto agree as follows:

      1.    ENGAGEMENT

            1.    ViaCord hereby engages PCT, and PCT accepts such engagement,
                  to provide the Services subject to and upon the terms and
                  conditions set forth in this Agreement.

      2.    PCT RESPONSIBILITIES AND REPRESENTATIONS

            1.    Subject to Section 3.2 hereof, PCT shall be responsible for
                  scheduling and performing the Services so as to meet ViaCord's
                  reasonable business and quality requirements.

            2.    PCT shall be responsible for communicating to ViaCord all
                  quantitative results generated as part of the Services in a
                  manner consistent with ViaCord's standard operating procedures
                  ("SOPs").

            3.    PCT will perform the Services in accordance with:

                  i.    all applicable legal requirements, including, but not
                        limited to, the laws of the states of New York and New
                        Jersey;

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                  ii.   ViaCord and PCT's SOPs. Where ViaCord procedures are to
                        be adhered to and where PCT procedures are to be adhered
                        to is detailed in PCT's SOP Number 01.041A, included
                        here as Attachment II. Each party agrees to provide the
                        other party with advance written notice of any material
                        changes to their respective relevant SOPs.

            4.    PCT will obtain and maintain licensure from the states of New
                  York and New Jersey for processing human umbilical cord blood
                  units ("HUCB' s") prior to processing any units originating in
                  either of these states.

            5.    PCT will provide reasonable cooperation for ViaCord to obtain
                  and maintain AABB accreditation for the Services. ViaCord will
                  pay all costs associated with obtaining and maintaining such
                  accreditation.

            6.    PCT agrees to be audited by ViaCord from time to time. All
                  audits shall occur at such time and with such frequency as
                  mutually agreed upon by both parties in advance; provided,
                  however, that ViaCord shall provide no less than twenty-four
                  (24) hours prior written notice to PCT prior to conducting an
                  audit pursuant to this Section 2.6. For the purpose of
                  conducting such audit, PCT shall make its facilities and
                  records available to ViaCord.

            7.    Prior to the commencement of the Services, PCT shall undergo
                  and pass a Vendor Qualification per ViaCord [*], which is
                  included here as Attachment III. PCT's approval as a vendor is
                  not to be unreasonably withheld by ViaCord.

            8.    PCT shall not provide the Services outside of its [*] without
                  the written consent of ViaCord.

            9.    PCT will ensure that all quarantine and long-term storage
                  freezers are connected to emergency backup power and
                  environmental monitoring and alarms systems.

            10.   Upon written request, and at ViaCord's expense, PCT will
                  prepare HUCBs for transplants in accordance with ViaCord's
                  Procedures.

      3.    VIACORD RESPONSIBILITIES AND REPRESENTATIONS

            1.    ViaCord will be responsible for the collection of cord blood
                  from patients and transportation of the cord blood to PCT's
                  laboratory.

            2.    To assist with daily scheduling, ViaCord will notify PCT as
                  soon as possible when an HUCB is due to arrive at PCT.
                  Typically this means notifying PCT once a patient goes into
                  labor, at which time ViaCord will notify PCT of the estimated
                  time of arrival of the HUCB at PCT.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

            3.    ViaCord will pay all costs associated with obtaining AABB
                  accreditation in connection with the Services.

            4.    ViaCord will pay all costs related to the preparation and
                  transportation of HUCBs for transplant.

            5.    ViaCord shall provide, at ViaCord's expense, all quarantine
                  and long-term storage freezers used for the storage of ViaCord
                  product. These freezers, and the capital equipment described
                  in Attachment I, shall remain ViaCord property and shall be
                  removed from PCT prior to the termination of this Agreement.

      4.    MUTUAL RESPONSIBILITIES AND REPRESENTATIONS OF BOTH PARTIES

            1.    The Parties agree to the terms of a Quality Agreement
                  ("Quality Agreement"), which is included here as Attachment
                  IV.

            2.    The Parties acknowledge and agree that each HUCB shall be the
                  property of the donor child. The parents of such child shall
                  have custodial ownership of such HUCB until the donor child
                  reaches the age of majority at which time the donor child
                  shall own the HUCB.

            3.    Prior to the commencement of Services, PCT and ViaCord shall
                  execute a Technology Transfer Protocol that is mutually
                  acceptable to both PCT and ViaCord. The Technology Transfer
                  Protocol shall be included here as Attachment V.

      5.    SERVICE CHARGES AND BILLING PROCEDURES

            1.    ViaCord shall compensate PCT for the Services according to the
                  fee schedule contained in Attachment I.

            2.    PCT shall invoice ViaCord at the time of service. Payment is
                  due within thirty (30) days of the date of each such invoice.
                  With respect to any compensation or portion thereof not paid
                  within ten (10) days after the date upon which the same are
                  due, ViaCord shall pay a late charge equal to the lesser of
                  eighteen percent (18.0%) per annum or the maximum allowable
                  rate of interest permitted by law. Upon any default by ViaCord
                  of any term or condition hereunder, with respect to its
                  obligations hereunder, which has not been cured by the
                  expiration of the applicable period under Section 8.2, PCT
                  may, with or without terminating this Agreement, exercise all
                  rights and remedies afforded by law.

            3.    The parties agree to negotiate in good faith any pricing
                  changes resulting from any material change to the Services.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

      6.    RELATIONSHIP OF THE PARTIES

            1.    The relationship between ViaCord and PCT with respect to the
                  Services shall be that of independent contracting parties. In
                  this regard, the parties agree that: (i) nothing in this
                  Agreement shall be construed to create a principal-agent,
                  employer-employee, or master-servant relationship or that of
                  partners or joint venturers between the parties; and (ii) each
                  party shall be liable for its own debts, obligations, acts,
                  and omissions, including the payment of all required
                  withholding, social security and other taxes on behalf of its
                  employees. None of the employees or contractors engaged by
                  either party shall be deemed employees of the other party.

      7.    INDEMNIFICATION; INSURANCE; DISCLAIMER

            1.    ViaCord shall indemnify, defend and hold harmless PCT, its
                  members, their affiliates, and their respective directors,
                  officers, and employees, from any and all costs, damages,
                  injunctions, suits, actions, fines, penalties, liabilities,
                  losses, settlements, claims, demands and expenses of any kind
                  (including, but not limited to, legal costs and reasonable
                  attorneys' fees) made by or on behalf of any party, person, or
                  governmental entity which result or arise out of any of the
                  acts or omission of ViaCord, its employees, officers,
                  directors and agents in connection with its obligations under
                  this Agreement. This provision shall survive the termination
                  of this Agreement, regardless of the reason for termination.

            2.    PCT shall indemnify, defend and hold harmless ViaCord, its
                  affiliates, directors, officers, and employees, from any and
                  all costs, damages, injunctions, suits, actions, fines,
                  penalties, liabilities, losses, settlements, claims, demands
                  and expenses of any kind (including, but not limited to, legal
                  costs and reasonable attorneys' fees) made by or on behalf of
                  any party, person, or governmental entity which result or
                  arise out of any of the acts or omission of PCT, its
                  employees, officers, directors and agents in connection with
                  its obligations under this Agreement. This provision shall
                  survive the termination of this Agreement, regardless of the
                  reason for termination.

            3.    The foregoing indemnification shall be contingent on: (i)
                  prompt written notice of any claim or proceeding subject to
                  such indemnity; (ii) cooperation in the defense and settlement
                  of such claim at the expense of the indemnifying party where
                  such indemnifying party is not a defendant, in the suit
                  involving such claim; (iii) prior written approval by
                  indemnifying party of any settlement, which approval shall not
                  be

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                  unreasonably withheld. The defense of such claim or assertion
                  and any action relating thereto shall be within the control of
                  the indemnifying party; provided, however, that the
                  indemnifying party's choice of counsel shall be reasonably
                  satisfactory to the indemnified party.

            4.    Each party shall maintain and keep in full effect throughout
                  the term of this Agreement, professional liability insurance
                  coverage in the amount of not less than [*] in the aggregate
                  per year for damages arising out of its performance hereunder.
                  Additionally, each party shall maintain and keep in full force
                  and effect throughout the term of this Agreement, other
                  insurances and coverages necessary for the operation of their
                  respective businesses, consistent with the standards in the
                  respective communities.

            5.    The parties acknowledge and agree that the Services are not
                  deemed to be products. Therefore, ViaCord acknowledges and
                  agrees that PCT does not in any way warrant the
                  merchantability or fitness for a particular purpose of the
                  Services; provided, however, that each party represents and
                  warrants to the other that its services small be performed in
                  a professional and workmanlike manner.

      8.    TERM; TERMINATION

            1.    The term of this Agreement shall be from the Effective Date
                  through June 30, 2002.

            2.    Either party to this Agreement may, at any time at its
                  election, terminate this Agreement forthwith and shall have no
                  further obligations hereunder by delivering written notice of
                  termination to the non-terminating party upon occurrence of
                  any one or more of the following events: (i) except with
                  respect to the payment obligations contained in Section 5
                  hereof, any material breach by either party of any of the
                  obligations established hereunder or other written agreements
                  between the parties if such breach continues for thirty (30)
                  days after receipt by the breaching party of notice specifying
                  such breach in reasonable detail; (ii) failure to make payment
                  in accordance with Section 5 hereof within ten (10) days of
                  the date upon which a payment is due pursuant to Section 5 if
                  such breach continues for three (3) days after receipt by the
                  breaching party of a demand for immediate payment; or (iii)
                  either party voluntarily files a petition in bankruptcy, makes
                  an assignment for the benefit of creditors, otherwise seeks
                  relief from its creditors under any federal or state
                  bankruptcy, insolvency, reorganization, or moratorium statute,
                  or either party is the subject of an involuntary petition in
                  bankruptcy which is not set aside within sixty (60) days of
                  its filing.

            3.    Upon termination of this Agreement, or upon any written
                  request from ViaCord, PCT agrees to relinquish to ViaCord any
                  HUCB(s) (contained in freezers), patient file(s), processing
                  record(s) and/or any capital equipment (including freezers)
                  paid for by ViaCord under this Agreement; provided, however,
                  that ViaCord has paid in full for the Services related to any
                  such

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                  HUCB(s), patient file(s), processing record(s) and/or capital
                  equipment. PCT shall provide any reasonable accommodations, at
                  ViaCord's expense, for the transfer of any such HUCB(s),
                  patient file(s), processing record(s) or capital equipment.

      9.    CONFIDENTIALITY

            1.    Confidential Information means any and all data, records,
                  reports, policies, knowledge, information and materials of a
                  party, including, without limitation, all data, records,
                  reports, policies, knowledge, information and materials
                  relating to this Agreement and/or such party's performance
                  hereunder. Without limitation of the foregoing, Confidential
                  Information of a party shall include all (i) technical
                  knowledge, information and materials of such party, such trade
                  secrets, data, concepts, ideas, information, processes,
                  formulae, improvements, inventions, computer programs, source
                  code, object code, micro code, documentation, diagrams, flow
                  charts, drawings, and experimental and development work
                  techniques; (ii) marketing and other business information of
                  such party, such as customer lists, marketing and business
                  plans, manuals and personnel records or data; and (iii)
                  Intellectual Property of such party. For purposes of this
                  Agreement, the terms and conditions of this Agreement shall be
                  deemed Confidential Information of each party. Confidential
                  Information shall not include information which: (1) is or
                  becomes publicly available without breach of this Agreement by
                  the party receiving the Confidential Information; (2) released
                  to the receiving party for disclosure by the disclosing party;
                  (3) known by the receiving party prior to the disclosure; or
                  (4) required to be disclosed by law or is compelled to be
                  disclosed by a court of competent jurisdiction; provided,
                  however, that notice is given to the other party of such
                  requirement as soon as possible and reasonable assistance is
                  rendered to such concerned parties, if requested, to prevent
                  such requirements becoming effective.

            2.    Each party shall (i) keep secret and retain in confidence, and
                  (ii) not use for its own benefit (except as expressly required
                  by this Agreement in connection with the performance of its
                  obligations hereunder or except as otherwise expressly
                  provided in this Agreement) the Confidential Information of
                  the other party. Upon termination of this Agreement for any
                  reason, subject only to ViaCord's right to retain patient
                  files pursuant to Section 8.3 hereof, each party shall
                  immediately deliver to the other party all Confidential
                  Information of such other party within its possession and/or
                  control.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

      10.   MISCELLANEOUS

            1.    The parties further agree that PCT shall retain and make
                  available upon request of ViaCord for a period of [*] years
                  after the furnishing of the Services, the contract and books,
                  documents and records which are necessary to certify the
                  nature and extent of the costs thereof when requested by the
                  Secretary of Health and Human Services or the Comptroller
                  General, or any of their duly authorized representatives. The
                  provision relating to the retention and production of
                  documents is included because of possible application of
                  Section 1861 (v) (1) (I) of the Social Security Act to this
                  Agreement; if this section should be found to be inapplicable,
                  then this clause shall be deemed to be inoperative and without
                  force and effect.

            2.    Any notice required by this Agreement shall be deemed
                  sufficient if it is in writing and delivered personally or by
                  certified mail, return receipt requested, or overnight mail by
                  a nationally-recognized carrier (e.g., Federal Express) or by
                  facsimile, if followed by a copy sent by one of the
                  aforementioned methods addressed to the party at its principal
                  office and to the party or his legal representatives at the
                  addresses written above or to such other addresses as they may
                  designate by giving notice pursuant to this Section 10.2.

            3.    This Agreement shall be governed by and construed in
                  accordance with the law of the State of New Jersey.

            4.    This Agreement may not be amended or revised except with the
                  mutual written consent of the parties hereto.

            5.    This Agreement may be executed in any number of counterparts,
                  each of which shall be deemed an original, but all of which
                  shall constitute one and the same instrument.

            6.    Not withstanding any other provision in this Agreement, the
                  parties remain responsible for ensuring that any service
                  provided hereunder complies with all pertinent provisions of
                  Federal, State and local statutes, rules and regulations.

            7.    If any provision of this Agreement is or becomes invalid,
                  illegal or unenforceable in any respect, the validity,
                  legality and enforceability of the remaining provision
                  contained herein shall not be affected thereby, and the
                  parties acknowledge and agree that each of them shall be
                  required to

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                  use their best efforts to negotiate a mutually acceptable
                  modification of provision(s) so as to satisfy applicable law.

            8.    Waiver, express or implied, of any default by either party of
                  any provision(s) of the Agreement shall not be deemed to be a
                  waiver of any other default. Waiver of any default shall not
                  affect the right of either party to require performance of the
                  defaulted provision at any further time.

            9.    No party may assign its rights and obligations under this
                  Agreement, except that each party has the right to assign its
                  rights and obligations hereunder to a successor to all or
                  substantially all of such party's assets related to this
                  Agreement, which successor agrees in writing to assume all
                  of such party's obligations hereunder. This Agreement shall
                  be binding upon and shall insure to the benefit of PCT and
                  ViaCord and their respective heirs, legal representatives,
                  successors and permitted assigns.

            10.   This Agreement represents the full understanding of the
                  parties regarding the subject matter and supercedes any prior
                  agreements between the parties on this subject.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

IN WITNESS THEREOF, the parties have hereunto set their hands and seals.

FOR VIACORD:

/s/ Robert A. Koshgarian                        12/7/01
-------------------------------------        -------------------------------
Robert A. Koshgarian                         Date
Vice President, Operations
ViaCell, Inc.

FOR PCT:

/s/ George S. Goldberger                         12/11/01
-------------------------------------        -------------------------------
George S. Goldberger                         Date
Chief Financial Officer
Progenitor Cell Therapy, L.L.C.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

       ATTACHMENT I. SCHEDULES OF SERVICES, FEES AND FORECASTED QUANTITIES

Services performed by PCT for ViaCord include:

     -    Receipt of cord blood units for processing
     -    Processing of units per ViaCord's Procedures and PCT's SOP's
     -    Quarantine storage in [*]
     -    Long-Term storage in [*]
     -    Creation of patient files, recording of processing data and [*] into
          patient files in accordance with ViaCord's Procedures
     -    Reporting of results to ViaCord's home office [*] after the
          conclusion of processing or the [*].

Fee(s):

     -    ViaCord shall pay [*] for each cord blood unit processed. This
          includes all materials and labor as well as all [*].
     -    ViaCord shall provide up to [*] for the purchase of capital
          equipment. These payments will be due upon receipt of invoice. This
          capital equipment shall remain ViaCord property and shall be removed
          from PCT prior to the termination of this Agreement.
     -    Within twelve (12) months of the Effective Date, ViaCord shall
          conduct contracted research at PCT totaling up to [*].
     -    ViaCord shall be responsible for all taxes related to the Services
          provided under this Agreement except for taxes on PCT's net income.
     -    ViaCord shall provide, at ViaCord's expense, all quarantine and
          long-term storage freezers. These freezers shall remain ViaCord
          property and shall be removed from PCT prior to the termination of
          this Agreement.
     -    ViaCord agrees to cover reasonable costs to secure appropriate
          storage space for the freezers used for long-term storage. The parties
          agree to negotiate in good faith regarding the size and functional
          requirements for any such space.

Forecasted Quantities:

December, 2001:  [*] Units
January, 2002:   [*] Units
February, 2002:  [*] Units
March, 2002:     [*] Units
April, 2002:     [*] Units
May, 2002:       [*] Units
June, 2002:      [*] Units

Notes on Forecasted Quantities:

     1.   All quantities contingent on ViaCord realizing these quantities in
          actual deliveries each month.

     2.   The parties agree to negotiate in good faith regarding quantities
          processed at PCT from April 1, 2002 through June 30, 2002 if ViaCord's
          own processing facility becomes operational during this period.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

             ATTACHMENT II. PCT'S SOP NUMBER [*] ("MATRIX OF SOP'S")

                                       [*]
       9 pages omitted pursuant to a request for confidential treatment.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                 HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                ATTACHMENT III. VIACORD VENDOR QUALIFICATION SOP

                                       [*]
       12 pages omitted pursuant to a request for confidential treatment.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                    AGREEMENT
                                       FOR
                 HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                  ATTACHMENT IV. PCT-VIACORD QUALITY AGREEMENT

                                QUALITY AGREEMENT

                                     BETWEEN

                                     VIACORD

                                       AND

                         PROGENITOR CELL THERAPY, L.L.C.

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>

Quality Agreement                                               07 December 2001

                               TABLE OF CONTENTS

INTRODUCTION..................................................................3
LIST OF CONTACTS..............................................................3
    Viacord...................................................................3
    PCT.......................................................................3
MANAGEMENT RESPONSIBILITY.....................................................3
REGULATORY COMPLIANCE.........................................................4
CORD BLOOD PROCUREMENT SERVICES...............................................4
UMBILICAL CORD BLOOD PROCESSING AND STORAGE...................................4
TESTING SERVICES..............................................................4
MEDICAL MANAGEMENT............................................................4
TECHNOLOGY TRANSFER...........................................................5
TRAINING AND COMPETENCY ASSESSMENT............................................5
CHANGE REQUESTS...............................................................5
CORRECTIVE ACTIONS............................................................5
DOCUMENT CONTROL..............................................................6
AUDITS........................................................................6
QUALITY ASSURANCE MEETINGS....................................................7
DISPUTE RESOLUTION............................................................7
SIGNATURES....................................................................7
APPENDIX A   LISTING OF SOPS..................................................8
APPENDIX B   CHANGE CONTROL FORM..............................................9

                                                                     Page 2 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

INTRODUCTION

Viacord (a wholly owned subsidiary of ViaCell, Inc.) is a premier provider of
umbilical cord blood (UCB) stem cell preservation services and Progenitor Cell
Therapy, L.L.C. (PCT) has developed substantial expertise in cell processing
technology. Viacord and PCT intend to enter into an agreement whereby PCT
performs processing, testing, and storage of UCB units for Viacord. This quality
agreement specifies the procedures and actions that Viacord and PCT will
undertake to ensure the maximum quality of the UCB units.

LIST OF CONTACTS

The following individuals from Viacord and PCT may be contacted regarding any
quality issues relating to procedures and policies described in this document:

VIACORD

[*], Manager of Quality Assurance, [*]

Bob Koshgarian, Vice President, Operations (617-320-4704,
rkoshgarian@viacellinc.com)

Kurt Gunter, SVP, Clinical & Reg. Affs./Gov. Relations, kgunter@viacellinc.com,
617-603-6164

PCT

Robert A. Preti, Ph.D., President & Chief Scientific Officer,
rpreti@progenitorcell.net, 201.291.2778

[*], QA Director, [*]

[*], National Director of laboratory Operations, [*]

MANAGEMENT RESPONSIBILITY

Both parties agree to define and document the responsibility, authority, and
relationship of personnel who perform, verify, or manage work related to the
product under this Agreement. The responsibility of these personnel is such that
there will be no limit in their efforts to maintain the quality and safety of
the products and services outlined in this Agreement. This will be accomplished
by their commitment to training, providing the best possible resources, internal
assessments and audits, and compliance with the regulations under which each
company operates.

                                                                     Page 3 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

REGULATORY COMPLIANCE

Both parties agree to establish standard operating procedures (SOPs) consistent
with industry standards and guidelines established by regulatory agencies (i.e.,
FDA, New York state, New Jersey state) and quality standards [i.e. American
Association of Blood Banks (AABB), Foundation for the Accreditation of
Hematopoietic Cell Therapy (FAHCT)]. The responsibility of maintaining
compliance with regulatory agencies is the sole responsibility of each company.

PCT will be responsible for obtaining all necessary licensures and
accreditations as required by local, state and federal laws, including those of
the states of New York and New Jersey. PCT will also, in good faith, work with
Viacord to achieve accreditation with AABB for its UCB processing services.

CORD BLOOD PROCUREMENT SERVICES

Viacord will be responsible for all cord blood procurement services. Viacord
will direct certain cord blood collections to PCT for processing and storage.
Viacord will be responsible for [*].

UMBILICAL CORD BLOOD PROCESSING AND STORAGE

PCT will be responsible for the processing and storage of UCB collections
shipped to PCT' s facilities as directed by Viacord. PCT will utilize reasonable
judgment based on current industry practices, relevant regulations and
scientific expertise to optimally manage all processing and storage services.

TESTING SERVICES

PCT will be responsible for all testing of UCB units stored for Viacord. Such
testing will be in compliance with all applicable local, state and federal
regulations, including those of the states of New York and New Jersey. All
testing will also be in compliance with applicable AABB guidelines. PCT will be
responsible for reporting of the testing results to Viacord in a timely manner.
Prior to initiation of all testing procedures, PCT will allow Viacord's
Department of Quality Assurance to review and approve specific testing methods.
[*]

MEDICAL MANAGEMENT

Viacord will be responsible for the medical management and all medical decisions
regarding the disposition of UCB collections (e.g., quarantine storage).
Viacord's medical director will consult with the director of PCT's laboratory
prior to any significant medical decision regarding the disposition of a
collection or UCB unit that has been processed. Viacord will be responsible for
the coordination of shipping UCB units for transplantation with the transplant

                                                                     Page 4 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

center. PCT shall be responsible for sample and dry shipper preparations for UCB
units for transplantation. Viacord will also be responsible for collection of
follow up medical data from patients transplanted with Viacord's UCB units.

TECHNOLOGY TRANSFER

Both parties agree to execute a prospectively defined technology transfer
protocol to ensure that all Viacord procedures will be successfully carried out
by PCT personnel and that all appropriate equipment used by PCT in the
processing, testing, and storage of Viacord UCB collections is appropriately
validated. The technology transfer document will be reviewed and approved by
both parties in advance of execution. Following the execution of the technology
transfer protocol, PCT will prepare a report and submit it to Viacord. Viacord
will review the report and recommend any required amendments or additional
experiments. Following approval of the final technology report by Viacord, the
technology will be considered to have been successfully transferred to PCT.

TRAINING AND COMPETENCY ASSESSMENT

All employees directly involved with the processing, testing, and storage of UCB
units must be properly trained and competency assessment must be completed and
documented. Training will be performed and documented by competent peers and/or
managers, utilizing all appropriate SOPs and manuals. Viacord will inspect
training and competency documentation during audits. Continued competency
assessment will be performed and documented at regular intervals. Competency
assessments will be conducted by direct managers, through questions and
observations directly related to the SOPs/manuals utilized in the processing,
testing and storage of UCB units.

CHANGE REQUESTS

Any and all changes made to the UCB processing, testing, and storage must go
through a Change Request process. A Change Control Form, (Appendix B) will be
completed and approved by appropriate individuals at PCT and Viacord. After such
approval, but prior to implementation, training will be conducted and
documented. No changes to the processing, testing, and storage of UCB units may
be implemented prior to PCT and Viacord' s approval of the change and all
appropriate training has been conducted and documented.

CORRECTIVE ACTIONS

PCT and Viacord will establish procedures for identifying, documenting and
implementing corrective actions. This exercise is critical to the adherence to
this Quality Agreement. The procedure will include, but not be limited to,
handling of error and accident reports and/or deviation reports, product
nonconformities, investigations resulting form any customer complaints, and
audits. Upon discovery of a deviation or error and accident, PCT shall notify
Viacord both verbally and in writing [*] of the occurrence. All investigations
will include the participation of both Viacord and PCT to determine the root
cause and corrective action required. All corrective actions will be tracked to
ensure implementation. Should a deviation, customer complaint, audit or other
situation identify a potential corrective action,

                                                                     Page 5 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

<PAGE>
Quality Agreement                                               07 December 2001

PCT will have [*] to respond to Viacord's recommendation and [*] to complete the
corrective action process.

DOCUMENT CONTROL

PCT agrees to establish and maintain procedures and processes for the
appropriate control of documents. The procedure shall contain guidelines for the
identification, filing, access, storage, maintenance, and disposition of all
documents associated with the processing, testing, and storage of Viacord's UCB
units. Documents shall be maintained to demonstrate that a product conforms to
specified requirements and quality systems. Documents from suppliers directly
concerning the quality and/or specification of any material used in the
processing, testing, and storage of UCB units will be retained as well. All
documents will be legible, retained in a way so as to be easily retrievable, and
stored in such a way as to prevent damage, deterioration, and loss. Documents
will be deemed confidential and shall be stored in such a way as to prevent the
accidental or unauthorized retrieval of this confidential information. All
documents must be maintained for a period of time in accordance with applicable
regulatory standards. This is to include, but not be limited to, documents
referencing facility, processing documents in regard to product trace ability,
testing results, and general documents in regard to corrective actions,
deviations, and error and accident reports. Documents not included in the AABB
Standards shall be retained for a length of time as determined by the business
needs and requirements of PCT and Viacord.

Viacord may have access to all Viacord UCB-related documents upon reasonable
prior notice. Upon request, PCT will provide originals or copies of all
requested documents to Viacord. If Viacord requests transfer of Viacord-related
documents from PCT, PCT will be responsible for the archival, inventory, and
shipment to a site specified by Viacord. The shipment costs and the logistics
surrounding the receipt of this shipment will be the responsibility of Viacord.
Viacord will assume the responsibility for document control for documents stored
off-site, once these documents are in the possession of Viacord. It is
understood that PCT may require copies of certain Viacord-related documents for
business purposes.

AUDITS

PCT and Viacord agree to procedures for external and internal audits. Both
internal and external assessments will be used to determine if the effectiveness
of the quality system in place and if it complies with requirements. Viacord
will perform an initial audit (prior to authorizing processing, testing, and
storage of UCB units), and may elect to perform additional audits throughout the
term of this agreement. Viacord will notify PCT at least 2 business days in
advance prior to an audit. Viacord will make available the written results of
the audit within 30 (thirty) days, post-audit. Furthermore, PCT agrees to
perform internal audits at regular intervals, as determined by, but not limited
to, regulations, trends in deviations, and corrective actions assigned by
Viacord. Records of any and all audits and all associated results shall be
maintained according to the requirements given in the Document Control section
of this document. PCT agrees to cooperate fully with any and all regulatory
inspections. A Viacord representative may be in attendance at PCT for any
regulatory and/or quality agency inspections.

                                                                     Page 6 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

QUALITY ASSURANCE MEETINGS

Representatives of the Departments of Quality Assurance from PCT and Viacord
will meet on a regular basis to analyze manufacturing deviations, abnormal
testing results for trends, and other quality issues, and recommend
implementation of corrections actions as necessary.

DISPUTE RESOLUTION

Viacord and PCT will make all efforts to resolve disputes amicably. In the event
of an irresolvable dispute, the two parties will select a mutually agreeable
independent arbiter to recommend the most appropriate action.

SIGNATURES

PCT and Viacord agree to follow all the provisions of this Quality Agreement to
the best of our abilities.

/s/ Robert Preti                              /s/ Kurt Gunter  6 Dec. 01
------------------------------------          ----------------------------------
Robert A. Preti, Ph.D.                        Kurt C. Gunter, M.D.
President & Chief Scientific Officer          Associate Medical Director
Progenitor Cell Therapy, L.L.C.               Viacord, Inc.

                                                                     Page 7 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

APPENDIX A LISTING OF SOPS

PROGENITOR CELL THERAPY STANDARD OPERATING PROCEDURE 01.041A "VIACORD SOP
MATRIX"

                                                                     Page 8 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Quality Agreement                                               07 December 2001

APPENDIX B  CHANGE CONTROL FORM

                           VIACORD CHANGE CONTROL FORM

CHECK ONE:  [ ] NEW              [ ] REVISION               [ ] OBSOLETION

DEPARTMENT:
           ---------------------------------------------------------------------

SOP/FORM/POLICY:
                ----------------------------------------------------------------

SOP/FORM/POLICY NO.:             REVISION NO.:               SUPERCEDES:
                    -------                    --------                  -------
DESCRIPTION OF CHANGE:
                       ---------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

REASON FOR PROPOSED CHANGE:
                           -----------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

OTHER DOCUMENTS AFFECTED:      [ ] YES           [ ] NO (If yes, please list)

INSTRUCTIONS: Please review the attached SOP/Form/Policy. Sign and date this
change control form and as indicated by the X. If revisions are required, DO NOT
sign, but return it immediately to Quality Assurance, stating the required
revisions on the document.

[ ]                                             [ ]
   -------------------------                       -----------------------------
         OPERATIONS                                 QUALITY ASSUR./REG. AFFAIRS

[ ]                                             [ ]
   -------------------------                       -----------------------------
          MARKETING                                 PATIENT & PHYSICIAN SERVICES

[ ]                                             [ ]
   -------------------------                       -----------------------------
       HUMAN RESOURCES                                       VALIDATION

[ ]                                             [ ]
   -------------------------                       -----------------------------
         PRESIDENT                                              OTHER

[ ]                                             [ ]
   -------------------------                       -----------------------------
            CEO                                                 OTHER

REGULATORY AFFAIRS FDA NOTIFICATION REQUIREMENTS:
[ ] FDA Approval required Prior to Implementation
[ ] FDA Notification Required   [ ] None
IMPLEMENTATION APPROVAL
EFFECTIVE DATE of NEW (or Revised) Document:
                                               ---------------------------------
OBSOLETION or DECLINED DATE:
                                               ---------------------------------
APPROVED BY (QA) / DATE:
                                               ---------------------------------

                                                                     Page 9 of 9

 Documentation of ViaCell, Inc. is considered proprietary and is made available
         for business operations and review by employees of ViaCell and
               regulatory agencies. Distribution to third parties
                    without written permission is prohibited.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

<PAGE>
                                    AGREEMENT
                                       FOR
                 HUMAN UMBILICAL CORD BLOOD PROCESSING SERVICES

                   ATTACHMENT V. TECHNOLOGY TRANSFER PROTOCOL

                                       [*]
       8 pages omitted pursuant to a request for confidential treatment.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.<PAGE>
                                                                   Exhibit 10.23

                                LICENSE AGREEMENT

         THIS AGREEMENT, effective as of January 18, 2001 ("EFFECTIVE DATE")
between THE GENERAL HOSPITAL CORPORATION, a not-for-profit corporation doing
business as Massachusetts General Hospital, having a place of business at Fruit
Street, Boston, Massachusetts 02114 ("GENERAL") and CEREBROTEC, INC., a
corporation having offices at 38 Broadway, Suite 313, Everett, MA 02149-2419
("CEREBROTEC").

         WHEREAS, under research programs funded by the GENERAL, the Children's
Medical Center Corporation ("CMCC") and the U.S. Government, the GENERAL and
CMCC through research conducted by Dr. Seth Finklestein and his colleagues,
including Dr. Evan Snyder of CMCC, has developed inventions pertaining to
treatments to enhance recovery from stroke;

         WHEREAS, GENERAL has filed U.S. and foreign Patent Applications
covering said inventions and all Dr. Finklestein's and his colleagues' rights,
title and interest in said applications have been assigned to GENERAL, except
that all Dr. Evan Snyder's rights, title and interest in certain JOINT PATENT
RIGHTS (as defined hereinbelow) have been assigned to CMCC, and that certain
other JOINT PATENT RIGHTS relating to the patent application filed October 27,
2000, serial number to be assigned, which is identified as MGH 1744.0, is
jointly owned by GENERAL and ViaCell, Inc.;

         WHEREAS, GENERAL represents to the best of its knowledge and belief
that, except as recited in the preceding paragraph, it is the owner of all
rights, title and interest in said patent applications and has the right and
ability to grant the license hereinafter described;

         WHEREAS, GENERAL and CMCC have entered into an Inter-Institutional
Agreement, effective January 18, 2001, under which CMCC has granted GENERAL the
right to grant licenses under CMCC's rights in certain JOINT PATENT RIGHTS (as
defined hereinbelow) on CMCC's behalf;

         WHEREAS, as a center for research and education, GENERAL and CMCC are
interested in licensing PATENT RIGHTS and JOINT PATENT RIGHTS and thus
benefiting the public and the GENERAL by facilitating the dissemination of the
results of its research in the form of useful products, but is without capacity
to commercially develop, manufacture, and distribute any such product; and

         WHEREAS, CEREBROTEC having such capacity, desires to commercially
develop, manufacture, use and distribute such products throughout the world;

         NOW THEREFORE, in consideration of the premises and of the faithful
performance of the covenants herein contained, the parties hereto agree as
follows:

                                 1. DEFINITIONS

         1.1      The term "ACCOUNTING PERIOD" shall mean each six month period
ending June 30 and December 31.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         1.2      The term "AFFILIATE" with respect to CEREBROTEC shall mean any
corporation or other legal entity controlling, controlled by or under common
control with CEREBROTEC. The term "AFFILIATE" with respect to GENERAL or CMCC
shall mean any company controlling, controlled by, or under common control with
GENERAL or CMCC, respectively. The term "control" means possession, direct or
indirect, of the powers to direct or cause the direction of the management and
policies of an entity, whether through the ownership of voting securities, by
contract or otherwise.

         1.3      The term "FIRST COMMERCIAL SALE" shall mean in each country
the first sale of any PRODUCT by CEREBROTEC, its AFFILIATES or SUBLICENSEES.

         1.4      The term "LICENSE FIELD" shall mean the diagnosis, treatment
or prevention of human and animal diseases.

         1.5      The Term "NET SALES PRICE" shall mean the GROSS SALES PRICE as
defined in (b) below received by CEREBROTEC or any of its AFFILIATES or
SUBLICENSEES ("SELLERS") for the sale or distribution of any PRODUCT to a final
customer who will be the end user of the PRODUCT and is not an AFFILIATE or
SUBLICENSEE ("CUSTOMER"), less (to the extent appropriately documented) the
following amounts actually paid out by CEREBROTEC, its AFFILIATE or SUBLICENSEE
or credited against the amounts received by them from the sale or distribution
of PRODUCT:

                  (a)      (i)      credits and allowances for price adjustment,
rejection, or return of PRODUCTS previously sold;

                           (ii)     rebates and cash discounts to purchasers
allowed and taken;

                           (iii)    amounts for transportation, insurance,
handling or shipping charges to purchasers;

                           (iv)     taxes, duties and other governmental charges
levied on or measured by the sale of PRODUCTS, whether absorbed by CEREBROTEC or
paid by the purchaser so long as CEREBROTEC's price is reduced thereby, but not
franchise or income taxes of any kind whatsoever;

                           (v)      for any sale in which the United States
government on the basis of its royalty-free license pursuant to 35 USC Sec.
202(c) to any PATENT RIGHT requires that the GROSS SALES PRICE of any PRODUCT
subject to such PATENT RIGHT be reduced by the amount of such royalty owed
GENERAL pursuant to paragraph 3.1, the amount of such royalty.

                  (b)      For any bona fide sale to a bona fide CUSTOMER by
CEREBROTEC or any of its AFFILIATES or SUBLICENSEES, the GROSS SALES PRICE
shall be the gross billing price of the PRODUCT.

                  (c)      If CEREBROTEC or any of its AFFILIATES or
SUBLICENSEES sell any PRODUCT in a bona fide sale as a component of a
combination of active functional elements, the GROSS SALES PRICE of the PRODUCT
shall be determined by multiplying the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
GROSS SALES PRICE of the combination by the fraction A over A+B, in which "A" is
the GROSS SALES PRICE of the PRODUCT portion of the combination when sold
separately during the ACCOUNTING PERIOD in the country in which the sale was
made, and "B" is the GROSS SALES PRICE of the other active elements of the
combination sold separately during said ACCOUNTING PERIOD in said country. In
the event that no separate sale of either such PRODUCT or active elements of the
combination is made during said ACCOUNTING PERIOD in said country, the GROSS
SALES PRICE of the PRODUCT shall be determined by multiplying the GROSS SALES
PRICE of such combination by the fraction C over C+D, in which "C" is the
standard fully-absorbed cost of the PRODUCT portion of such combination, and "D"
is the sum of the standard fully-absorbed costs of the other active elements
component(s), such costs being arrived at using the standard accounting
procedures of CEREBROTEC which will be in accord with generally accepted
accounting practices.

                  (d)      If a SELLER commercially uses or disposes of any
PRODUCT by itself (as opposed to a use or disposition of the PRODUCT as a
component of a combination of active functional elements) other than in a bona
fide sale to a bona fide CUSTOMER, the GROSS SALES PRICE hereunder shall be the
price which would be than payable in an arm's length transaction with such a
CUSTOMER. If a SELLER commercially uses or disposes of any PRODUCT as a
component of a combination of active functional elements other than in a bona
fide sale to a bona fide customer, the GROSS SALES PRICE of the PRODUCT shall be
determined in accordance with paragraph (c) above, using as the GROSS SALES
PRICE of the combination that price which would be then payable in an arm's
length transaction.

                  (e)      Transfer of a PRODUCT within CEREBROTEC or between
CEREBROTEC and an AFFILIATE for sale by the transferee shall not be considered a
sale, commercial use or disposition for the purpose of the foregoing paragraphs;
in the case of such transfer the GROSS SALES PRICE shall be based on sale of the
PRODUCT by the transferee.

         1.6.     The term "OPTION AGREEMENT" shall mean that certain Option
Agreement pertaining to subject matter of this Agreement and to certain of the
patent applications licensed to CEREBROTEC hereunder, that is one of two Option
Agreements between GENERAL and CEREBROTEC dated August 12, 1999.

         1.7.     The term "PATENT RIGHT" shall mean the U.S. Patent
Applications filed by Dr. Seth Finklestein and colleagues listed on Appendix A,
or the equivalent of such application, including any division, continuation or
any foreign patent application or Letters Patent of the equivalent thereof
issuing thereon or reissue, reexamination or extension thereof. PATENT RIGHTS
shall also include those claims in any continuation-in-part of the
aforementioned patent application which claim an invention described or claimed
in said patent application.

         1.8      The term "JOINT PATENT RIGHT" shall mean [*] or the equivalent
of such applications, including any division, continuation, substitute or any
foreign patent application or Letters Patent or the equivalent

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
thereof issuing thereon or reissue, reexamination or extension thereof. JOINT
PATENT RIGHT shall also include those claims in any continuation-in-part of the
aforementioned patent application which claim an invention described or claimed
in said patent application.

         1.9      The term "PRODUCT" shall mean any article, device,
composition, method or service, the manufacture, use, or sale of which

                  (a)      absent the licenses granted herein, would infringe a
VALID CLAIM of any PATENT RIGHT, or

                  (b)      does not infringe a VALID CLAIM of any PATENT RIGHT
licensed to CEREBROTEC hereunder but the discovery, development, manufacture or
use of which employs TECHNOLOGICAL INFORMATION.

         1.10     The term "SUBLICENSEE" shall mean any non-AFFILIATE third
party granted a license by CEREBROTEC or by an AFFILIATE to make, have made, use
or sell any PRODUCT. As used in this Agreement, "SUBLICENSEE" shall include,
without limitation, any third party to whom CEREBROTEC or an AFFILIATE has
granted, directly or indirectly, the fight to distribute a PRODUCT, provided
that such third party has the responsibility in whole or in part for marketing
and/or promotion of the PRODUCT within the territory for which such distribution
rights are granted.

         1.11     The term "SUBLICENSE REVENUE" shall mean any payments that
CEREBROTEC receives from a SUBLICENSEE in consideration of the sublicense of the
rights granted to CEREBROTEC under Article 2 including, without limitation,
license fees, milestone payments and license maintenance fees, but excluding the
following payments: (a) royalties on NET SALES by the SUBLICENSEE for which
GENERAL receives its royalties pursuant to paragraph 5.1, (b) payments made in
consideration of the issuance of equity or debt securities of CEREBROTEC at fair
market value, and (c) payments specifically committed to the research or
development of PRODUCTS actually conducted by or for CEREBROTEC.

         1.12     The term "TECHNOLOGICAL INFORMATION" shall mean any research
data, designs, formulas, process information, clinical data and other
information pertaining to any invention claimed in PATENT RIGHT which is known
to Dr. Finklestein on the EFFECTIVE DATE.

         1.13     The term "VALID CLAIM" shall mean any claim of any PATENT
RIGHT that has not been (i) finally rejected or (ii) declared invalid by a
patent office or court of competent jurisdiction in any unappealed and
unappealable decision.

         1.14     The term "FINANCING" shall mean either (i) the sale by
CEREBROTEC of securities, which sales generate gross aggregate cash proceeds to
CEREBROTEC, in one or more closings, of at least $1,000,000 (ii) any sale of a
majority of the outstanding shares of CEREBROTEC to a third party regardless of
the amount of CEREBROTEC's compensation, or (iii) the merger or acquisition of
CEREBROTEC with a third party regardless of whether CEREBROTEC's compensation
for such sale is in cash and regardless of the amount of CEREBROTEC's
compensation.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         1.15     The term "CLOSING OF THE FINANCING" shall mean the closing of
either (i) the particular round of the FINANCING which results in the gross
aggregate cash proceeds to CEREBROTEC of all rounds of the FINANCING closed to
that date being at least $1,000,000, (ii) the sale of a majority of shares of
CEREBROTEC to a third party, or (iii) the merger or acquisition of CEREBROTEC
with a third party.

                                   2. LICENSE

         2.1      GENERAL hereby grants CEREBROTEC, to the extent not prohibited
by the Untied States Government or by contractual obligations to any other
sponsor of research at GENERAL or CMCC;

                  (a)      an exclusive, worldwide, royalty-bearing license in
the LICENSE FIELD under GENERAL's and CMCC's rights in PATENT RIGHTS and JOINT
PATENT RIGHTS to make, have made, use and sell PRODUCTS;

                  (b)      to the extent an exclusive license is not available
to CEREBROTEC in a country, due to legal or regulatory action in such country, a
non-exclusive, royalty-bearing license in the LICENSE FIELD under PATENT RIGHTS
and JOINT PATENT RIGHTS to make, have made, use and sell PRODUCTS;

                  (c)      the right to sublicense PATENT RIGHTS and JOINT
PATENT RIGHTS exclusively licensed to CEREBROTEC.

         The above licenses to sell PRODUCTS include the right to grant to the
purchaser of products from CEREBROTEC, its AFFILIATES, and SUBLICENSEES the
right to use such purchased PRODUCTS in a method coming within the scope of
PATENT RIGHT.

         2.2      It is understood that the granting of any license hereunder is
subject to GENERAL's and GENERAL's AFFILIATES' right to make and to use the
subject matter described and claimed in all PATENT RIGHTS and JOINT PATENT
RIGHTS, and CMCC's and CMCC's AFFILIATES' right to make and to use the subject
matter claimed in JOINT PATENT RIGHT for research, clinical and educational
purposes but for no other purpose, and that if federal funding supported any
PATENT RIGHT, CEREBROTEC's license will be subject to the rights, conditions and
limitations imposed by U.S. law including without limitation the royalty-free
non-exclusive license granted to the U.S. government (see 35 U.S.C. Section 202
et. seq. and regulations pertaining thereto).

         2.3      Within three (3) months of EFFECTIVE DATE, upon request by
CEREBROTEC, GENERAL shall disclose to CEREBROTEC, TECHNOLOGICAL INFORMATION
which CEREBROTEC will be entitled to use to the extent such use does not
infringe any patent not licensed to CEREBROTEC hereunder.

         2.4      It is understood that nothing herein shall be construed to
grant CEREBROTEC a license express or implied under any patent owned solely or
jointly by GENERAL or CMCC other that the PATENT RIGHTS and JOINT PATENT RIGHTS
expressly licensed hereunder.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                          3. DUE DILIGENCE OBLIGATIONS

         3.1      CEREBROTEC shall itself, or through its AFFILIATES or
SUBLICENSEES, use its best efforts to develop and make commercially available
PRODUCTS for commercial sales and distribution throughout the world in the
LICENSE FIELD. Such efforts shall include the following: within twenty-four (24)
months after the EFFECTIVE DATE, achieving either (i) the CLOSING OF THE
FINANCING; or (ii) entering into a partnering agreement with a SUBLICENSEE under
which said SUBLICENSEE agrees to fund research or product development at
CEREBROTEC in an amount of at least [*] for at least two years.

         Within twenty-four (24) months following the EFFECTIVE DATE, GENERAL
and CEREBROTEC shall meet to: (i) agree either to adopt further time-limited
performance objectives, or to adopt amendments to the annual minimum payments
specified in paragraph 5.5, to ensure that CEREBROTEC uses its best efforts to
develop and make commercially available PRODUCTS based on PATENT RIGHTS and
JOINT PATENT RIGHTS for commercial sales and distribution throughout the world;
and (ii) identify such objectives in the event of their necessity. Such
objectives may include requirements such as taking the following steps within
defined timeframes; to complete all animal toxicity tests required in connection
with securing U.S. Food and Drug Administration approval of clinical evaluations
thereof; to initiate and thereafter diligently pursue clinical evaluations of a
PRODUCT and in connection therewith take all actions reasonably necessary under
the Food, Drug and Cosmetic Act (21 USC 301-391); to introduce PRODUCT on a
worldwide basis.

         Provided, however, that GENERAL shall not unreasonably withhold its
consent to any revision in any time periods specified herein or established in
accordance with this paragraph 3.1 whenever requested in writing by CEREBROTEC
and supported by evidence of technical difficulties or delays that the parties
could not have reasonably avoided. Failure to achieve any objective within the
above stated time periods, or within the time periods established in accordance
with this paragraph 3.1 or within any extension granted by GENERAL shall result
in GENERAL having the right to cancel upon thirty (30) days notice any exclusive
license granted hereunder or convert any exclusive license to a non-exclusive
license.

         3.2      At intervals no longer than every six (6) months, CEREBROTEC
shall report in writing to GENERAL on progress made toward the development and
commercialization of PRODUCTS.

             4. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
                             AND JOINT PATENT RIGHTS

         4.1      (a)      GENERAL shall be responsible for the preparation,
filing, prosecution and maintenance of all patent applications and patents
included in PATENT RIGHTS and JOINT PATENT RIGHTS, at CEREBROTEC's expense.
GENERAL shall control patent prosecution of all PATENT RIGHTS and JOINT PATENT
RIGHTS using outside patent counsel acceptable to CEREBROTEC in such countries
as CEREBROTEC shall reasonably specify.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                  (b)      CEREBROTEC shall reimburse GENERAL for all reasonable
costs for the preparation, filing, prosecution and maintenance of all PATENT
RIGHTS and JOINT PATENT RIGHTS ("Costs") incurred by GENERAL prior to January 1,
2001 (exclusive of Costs previously reimbursed by CEREBROTEC under the Option
Agreements) ("PAST PATENT COSTS"), to be payable upon the CLOSING OF THE
FINANCING, however, if the CLOSING OF THE FINANCING has not occurred by the
first anniversary of the EFFECTIVE DATE, CEREBROTEC shall pay GENERAL forty
percent (40%) of the PAST PATENT COSTS on said first anniversary and shall pay
the balance of said amount upon the earlier of the CLOSING OF THE FINANCING or
the second anniversary of the EFFECTIVE DATE. PAST PATENT COSTS are estimated at
one hundred thirty thousand dollars ($130,000), however, GENERAL shall provide
CEREBROTEC with an accounting of these costs, supported by appropriate
documentation, within sixty (60) days of the execution of this Agreement (but in
no event later than the first invoice to be provided to CEREBROTEC under
subparagraph (c) below), and the total costs supported by such accounting and
documentation shall be considered the amount of PAST PATENT COSTS to be
reimbursed by CEREBROTEC in accordance with this paragraph 4.1(b).

                  (c)      Subject to paragraph 4.2, CEREBROTEC shall reimburse
GENERAL for all Costs incurred by GENERAL from and after January 1, 2001, within
thirty (30) days of receipt of invoices from GENERAL or its outside counsel as
contemplated herein.

         4.2      With respect to any PATENT RIGHT, each document or a draft
thereof pertaining to the filing, prosecution, or maintenance of such PATENT
RIGHT, including but not limited to each patent application, office action,
response to office action, request for terminal disclaimer, and request for
reissue or reexamination of any patent issuing from such application shall be
provided to CEREBROTEC as follows. Documents received from any patent office or
counsel's analysis thereof shall be provided promptly after receipt. For a
document to be filed in any patent office, a draft of such document shall be
provided sufficiently prior to its filing, to allow for review and comment by
CEREBROTEC. CEREBROTEC shall have the right to participate in, comment upon and
make recommendations regarding the course of patent prosecution, which
recommendations GENERAL agrees to follow except to the extent such
recommendations result, in GENERAL's determination, in an unwarranted narrowing
of PATENT RIGHTS and/or JOINT PATENT RIGHTS.

         4.3      If CEREBROTEC shall elect not to pay or continue to pay the
Costs for any PATENT RIGHT, CEREBROTEC shall so notify GENERAL promptly and
CEREBROTEC shall thereafter be relieved of the obligation to pay any additional
Costs regarding such PATENT RIGHT incurred after the receipt of such notice by
GENERAL. Such U.S. or foreign patent application or patent shall thereupon cease
to be a PATENT RIGHT hereunder and GENERAL shall be free to prosecute or
maintain such PATENT RIGHT at its own expense and to license its rights to that
particular PATENT RIGHT to any other party on any terms.

                                   5. PAYMENTS

         5.1      Royalties. Beginning with the FIRST COMMERCIAL SALE in any
country, on all sales of PRODUCTS anywhere in the world by CEREBROTEC, its
AFFILIATES or SUBLICENSEES, CEREBROTEC shall pay GENERAL royalties in accordance
with the following schedule, such undertaking and schedule having been agreed to
for the purpose of

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
reflecting and advancing the mutual convenience of the parties. For each PRODUCT
sold by CEREBROTEC or its AFFILIATES and SUBLICENSEES;

                  (a)      [*] of the NET SALES PRICE so long as the PRODUCT,
its manufacture, use or sale is converted by a VALID CLAIM of any PATENT RIGHT
licensed exclusively to CEREBROTEC;

                  (b)      [*] of the NET SALES PRICE whenever the PRODUCT, its
manufacture, use or sale is covered by a VALID CLAIM of any PATENT RIGHT
licensed non-exclusively to CEREBROTEC in the country in question; and

                  (c)      During each of the ten (10) years next following the
FIRST COMMERCIAL SALE anywhere in the world by CEREBROTEC, its AFFILIATES or
SUBLICENSEES, [*] of the NET SALES PRICE of PRODUCT on which no royalty is
payable under paragraph 5.1(a) or 5.1(b) above.

         5.2      (a)      In the event that more than one royalty rate under
paragraph 5.1 is applicable to a PRODUCT, the highest of the applicable
royalties shall apply.

                  (b)      Only one royalty under paragraph 5.1 shall be due and
payable to GENERAL by CEREBROTEC for any PRODUCT regardless of the number of
PATENT RIGHTS and/or JOINT PATENT RIGHTS covering such PRODUCT.

                  (c)      In the event CEREBROTEC determines that it is
necessary to license any technology of a third party in order to make, use or
sell PRODUCTS, then the royalty payment due to GENERAL under Section 5.1(a)
shall be reduced by fifty percent (50%) of the royalties paid by CEREBROTEC
under such third party licenses; provided, however, that in no event shall the
royalty payable to GENERAL under Section 5.1(a) be reduced by more than fifty
percent (50%) in any ACCOUNTING PERIOD.

                  (d)      If any license granted pursuant to Article 2 shall be
or become non-exclusive and GENERAL shall license any PATENT RIGHT to another
licensee for the purpose of making, using or selling PRODUCTS and accept a
royalty or royalties more favorable to such licensee than herein provided for
CEREBROTEC, GENERAL shall give written notice thereof to CEREBROTEC and as of
the EFFECTIVE DATE of such more favorable royalty or royalties, CEREBROTEC's
obligation hereunder to pay royalty or royalties to GENERAL shall be revised to
the more favorable rate.

                  (e)      In the event that the royalty paid to GENERAL is a
significant factor in the return realized by CEREBROTEC so as to diminish
CEREBROTEC's capability to respond to competitive pressures in the market,
GENERAL agrees to consider a reasonable reduction in the royalty paid to GENERAL
as to each such PRODUCT for the period during which such market condition
exists. Factors determining the size of the reduction will include profit margin
on PRODUCT and on analogous products, prices of competitive products, total
prior sales by CEREBROTEC, and CEREBROTEC's expenditures in PRODUCT development.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         5.3      Sublicensee Revenue. Subject to Section 5.4, CEREBROTEC shall
pay GENERAL [*] of all SUBLICENSEE REVENUE received by CEREBROTEC. Such payments
shall be due and payable within sixty (60) days after CEREBROTEC receives the
relevant payment from the SUBLICENSEE.

         5.4      Milestones. CEREBROTEC shall pay GENERAL the following amounts
upon the occurrence of the following milestones:

                  (a)      upon commencement of the first Phase III clinical
trial of a PRODUCT by CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of
(i) [*] or (ii) [*] of any SUBLICENSEE REVENUE received by CEREBROTEC
attributable to the commencement of the first Phase III clinical trial of such
PRODUCT;

                  (b)      upon filing with the FDA of the first NDA, 510(k),
PMA or PMA Supplement, or comparable application with respect to a PRODUCT by
CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of (i) [*] or (ii) [*] of
any SUBLICENSEE REVENUE received by CEREBROTEC attributable to the filing with
the FDA of the first NDA, 510(k), PMA or PMA Supplement, or comparable
application with respect to such PRODUCT; and

                  (c)      upon approval by the FDA of the first NDA, 510(k),
PMA or PMA Supplement, or comparable application with respect to a PRODUCT by
CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of (i) [*] or (ii) [*] of
any SUBLICENSEE REVENUE received by CEREBROTEC attributable to the approval by
the FDA of the first NDA, 510(k), PMA or PMA Supplement, or comparable
application with respect to such PRODUCT.

         5.5      Annual Minimum Royalty. CEREBROTEC shall pay GENERAL an annual
minimum royalty of [*] per calendar year, commencing with the calendar year
ending December 31, 2001. Said annual minimum royalty shall increase to [*] per
calendar year, commencing with the calendar year ending December 31, 2004, and
to [*] per calendar year, commencing with the calendar year ending December 31,
2008. The annual minimum royalty payment for each year shall be due within
thirty days of the end of such year, and CEREBROTEC may credit the annual
minimum royalty in each year against any payments otherwise due GENERAL under
this Article 5 for such calendar year.

         5.6      The payments due under this Agreement shall, if overdue, bear
interest until payment at a per annum rate equal to one percent (1%) above the
prime rate in effect at the Fleet Bank on the due date, not to exceed the
maximum permitted by law. The payment of such interest shall not preclude
GENERAL from exercising any other rights it may have as a consequence of the
lateness of any payment.

                             6. REPORTS AND PAYMENTS

         6.1      CEREBROTEC shall keep, and shall cause each of its AFFILIATES
and SUBLICENSEES, if any, to keep full and accurate books of accounts containing
all particulars that may be necessary for the purpose of calculating all
royalties payable to GENERAL. Such

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
books of accounts shall be kept at their principal place of business and, with
all necessary supporting data shall, during all reasonable times for the three
(3) years next following the end of the calendar year to which each shall
pertain be open for inspection at reasonable times by GENERAL or its designee at
GENERAL's expense for the purpose of verifying royalty statements or compliance
with this Agreement.

         6.2      In each year the amount of royalty due shall be calculated
semiannually as of the end of each ACCOUNTING PERIOD and shall be paid
semiannually within the sixty (60) days next following such date, every such
payment to be supported by the accounting prescribed in paragraph 6.3 and to be
made in United States currency. Whenever conversion from any foreign currency
shall be required, such conversion shall be at the rate of exchange thereafter
published in the Wall Street Journal for the business day closest to the end of
the applicable ACCOUNTING PERIOD.

         6.3      With each semiannual payment, CEREBROTEC shall deliver to
GENERAL a full and accurate accounting to include at least the following
information:

                  (a)      Quantity of each PRODUCT sold or leased (by country)
by CEREBROTEC, and its AFFILIATES or SUBLICENSEES;

                  (b)      Total billings for each PRODUCT (by country);

                  (c)      Quantities of each PRODUCT used by CEREBROTEC and its
AFFILIATES or SUBLICENSEES;

                  (d)      Names and addresses of all SUBLICENSEES of
CEREBROTEC; and

                  (e)      Total royalties payable to GENERAL.

                                 7. INFRINGEMENT

         7.1      GENERAL will protect its PATENT RIGHTS and JOINT PATENT RIGHTS
from infringement and prosecute infringers when, in its sole judgement, such
action may be reasonably necessary, proper and justified.

         7.2      If CEREBROTEC shall have supplied GENERAL with written
evidence demonstrating to GENERAL'S reasonable satisfaction prima facie
infringement of a claim of a PATENT RIGHT in the LICENSE FIELD by a third party,
CEREBROTEC may by notice request GENERAL to take steps to protect the PATENT
RIGHT. GENERAL shall notify CEREBROTEC within three (3) months of the receipt of
such notice whether GENERAL intends to prosecute the alleged infringement. If
GENERAL notifies CEREBROTEC that it intends to so prosecute, GENERAL shall,
within three (3) months of its notice to CEREBROTEC either (i) cause
infringement to terminate or (ii) initiate legal proceedings against the
infringer. In the event GENERAL notifies CEREBROTEC that GENERAL does not intend
to prosecute said infringement CEREBROTEC may, upon notice to GENERAL, initiate
legal proceedings against the infringer at CEREBROTEC's expense and in GENERAL's
name if so required by law. No settlement, consent judgment or other voluntary
final disposition of the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
suit which invalidates or restricts the claims of such PATENT RIGHTS and/or
JOINT PATENT RIGHTS may be entered into without the consent of GENERAL, which
consent shall not be unreasonable withheld. CEREBROTEC shall indemnify GENERAL
against any order for payment that may be made against GENERAL in such
proceedings.

         7.3      In the event one party shall initiate or carry on legal
proceedings to enforce any PATENT RIGHT against any alleged infringer, the other
party shall fully cooperate with and supply all assistance reasonably requested
by the party initiating or carrying on such proceedings. The party which
institutes any suit to protect or enforce a PATENT RIGHT shall have sole control
of that suit and shall bear the reasonable expenses (excluding legal fees)
incurred by said other party in providing such assistance and cooperation as is
requested pursuant to this paragraph. The party initiating or carrying on such
legal proceedings shall keep the other party informed of the progress of such
proceedings and said other party shall be entitled to counsel in such
proceedings but at its own expense. Any award paid by third parties as the
result of such proceedings (whether by way of settlement or otherwise) shall
first be applied to reimbursement of the unreimbursed legal fees and expenses
incurred by either party and then the remainder shall be divided between the
parties as follows:

                  (a)      (i)      If the amount is based on lost profits,
CEREBROTEC shall receive an amount equal to the damages the court determines
CEREBROTEC has suffered as a result of the infringement less the amount of any
royalties that would have been due GENERAL on sales of PRODUCT lost by
CEREBROTEC as a result of the infringement had CEREBROTEC made such sales; and

                           (ii)     GENERAL shall receive an amount equal to the
royalties it would have received if such sales had been made by CEREBROTEC; and

                  (b)      As to awards other than those based on lost profits,
sixty (60) percent to the party initiating such proceedings and forth (40)
percent to the other party.

         7.4      For the purpose of the proceedings referred to in this Article
7, the GENERAL and CEREBROTEC shall permit the use of their names and shall
execute such documents and carry out such other acts as may be necessary. The
party initiating or carrying on such legal proceedings shall keep the other
party informed of the progress of such proceedings and said other party shall be
entitled to counsel in such proceedings but at its own expense, said expenses to
be off-set against any damages received by the party brining suit in accordance
with the foregoing paragraph 7.3.

         7.5      In the event that a declaratory judgment action or any other
action alleging invalidity, unenforceability, or non-infringement of any of the
PATENT RIGHTS or JOINT PATENT RIGHTS shall be brought against CEREBROTEC,
CEREBROTEC shall promptly notify GENERAL. CEREBROTEC shall have the sole right
to defend such action at its own expense, unless GENERAL, within thirty (30)
days after notification of such action, elects to intervene and take over the
sole defense of the action at its own expense.

                               8. INDEMNIFICATION

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         8.1      (a)      CEREBROTEC shall indemnify, defend and hold harmless
GENERAL, CMCC and their trustees, officers, medical and professional staff,
employees, and agents and their respective successors, heirs and assigns (the
"Indemnitees"), against any liability, damage, loss or expense (including
reasonable attorney's fees and expenses of litigation) incurred by or imposed
upon the Indemnitees or any one of them in connection with any claims, suits,
actions, demands or judgments arising out of any theory of product liability
(including, but not limited to, actions in the form of tort, warranty, or strict
liability) concerning any product, process or service made, used or sold
pursuant to any right or license granted under this Agreement.

                  (b)      CEREBROTEC's indemnification under (a) above shall
not apply to any liability, damage, loss or expense to the extent that it is
directly attributable to the negligent activities, reckless misconduct or
intentional misconduct of the Indemnitees.

                  (c)      CEREBROTEC agrees, at its own expense to provide
attorneys reasonably acceptable to the GENERAL to defend against any actions
brought or filed against any party indemnified hereunder with respect to the
subject of indemnity contained herein, whether or not such actions are
rightfully brought.

                  (d)      This paragraph 8.1 shall survive expiration or
termination of this Agreement.

         8.2      (a)      Beginning at such time as any such product, process
or service is being commercially distributed or sold (other than for the purpose
of obtaining regulatory approvals) by CEREBROTEC or by a licensee, affiliate or
agent of CEREBROTEC, CEREBROTEC shall, at its sole cost and expense, procure and
maintain commercial general liability insurance in amounts not less than
$2,000,000 per incident and $2,000,000 annual aggregate and naming the
Indemnitees as additional insureds. Such commercial general liability insurance
shall provide (i) product liability coverage and (ii) broad form contractual
liability coverage for CEREBROTEC's indemnification under paragraph 8.1 of this
Agreement. If CEREBROTEC elects to self-insure all or part of the limits
described above (including deductibles or retentions which are in excess of
$250,000 annual aggregate) such self-insurance program must be acceptable to the
GENERAL, CMCC and the Risk Management Foundation. The minimum amounts of
insurance coverage required under this paragraph 8.2 shall not be construed to
create a limit of CEREBROTEC's liability with respect to its indemnification
under paragraph 8.1 of this Agreement.

                  (b)      CEREBROTEC shall provide GENERAL with written
evidence of such insurance upon request of GENERAL. CEREBROTEC shall provide
GENERAL with written notice at least fifteen (15) days prior to the
cancellation, non-renewal or material change in such insurance; if CEREBROTEC
does not obtain replacement insurance providing comparable coverage prior to the
expiration of such fifteen (15) day period, GENERAL shall have the right to
terminate this Agreement effective at the end of such fifteen (15) day period
without notice or any additional waiting periods.

                  (c)      CEREBROTEC shall maintain such commercial general
liability insurance beyond the expiration or termination of this Agreement
during (i) the period that any such product, process, or service is being
commercially distributed or sold (other than for the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
purpose of obtaining regulatory approvals) by CEREBROTEC or by a licensee,
affiliate or agent of CEREBROTEC and (ii) a reasonable period after referred to
in (c)(i) above which in no even shall be less than fifteen (15) years.

                  (d)      This paragraph 8.2 shall survive expiration or
termination of this Agreement.

         8.3      OTHER THAN WARRANTIES SET FORTH HEREIN, GENERAL MAKES NO
WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, TRADE SECRET, TANGIBLE
RESEARCH PROPERTY, INFORMATION OR DATA LICENSED OR OTHERWISE PROVIDED TO
CEREBROTEC HEREUNDER AND HEREBY DISCLAIMS THE SAME.

         8.4      GENERAL represents that, to the best of its knowledge as of
the EFFECTIVE DATE, there are no contractual obligations to other sponsors of
research at GENERAL or CMCC that would prohibit the granting of the rights and
licenses granted to CEREBROTEC herein.

                                 9. TERMINATION

         9.1      Unless otherwise terminated as provided for in this Agreement,
the license to PATENT RIGHTS and JOINT PATENT RIGHTS granted hereunder will
continue on a country by country basis:

                  (a)      for one (1) year after the date CEREBROTEC, its
AFFILIATES, or SUBLICENSEES shall last sell any PRODUCT in such country, it
being understood that GENERAL shall have the right to terminate such license
upon written notice in any country in the event that after the FIRST COMMERCIAL
SALE of PRODUCT in such country there is a continuous one (1) year period in
which no PRODUCT is sold in such country, provided such sale is not prevented by
force majeure, government regulation or intervention, or institution of a law
suit by any third party, or

                  (b)      until the last to expire of any PATENT RIGHT, the
claims of which but for this Agreement would be infringed by the manufacture,
use or sale of any PRODUCT in the applicable country, whichever shall first
occur.

         9.2      If either party shall fail to faithfully perform any of its
obligations under this Agreement except the due diligence milestones specified
in Article 3 herein, the nondefaulting party may give written notice of the
default to the defaulting party. Unless such default is corrected within thirty
(30) days after such notice, the notifying party may terminate this Agreement
and the license hereunder upon thirty (30) days' prior written notice, provided
that only one such thirty (30) day grace period shall be available in any twelve
(12) month period with respect to a default of any particular provision
hereunder. Thereafter notice of default of said provision shall constitute
termination.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         9.3      In the event that any license granted to CEREBROTEC under this
Agreement is terminated, any sublicense under such license granted prior to
termination of said license shall remain in full force and effect, provided
that:

                  (a)      the SUBLICENSEE is not then in breach of its
sublicense agreement;

                  (b)      the SUBLICENSEE agrees to be bound to GENERAL as the
licensor under the terms and conditions of its sublicense agreement, as modified
by the provisions of this paragraph 9.3;

                  (c)      the SUBLICENSEE, at GENERAL's written request,
assumes in a signed writing the same obligations to GENERAL as those assumed by
CEREBROTEC under Articles 8 and 10 hereof;

                  (d)      GENERAL shall have the right to receive the greater
of (a) any payments payable to CEREBROTEC under such sublicense agreement to the
extent they are reasonably and equitably attributable to such SUBLICENSEE's
right under such sublicense to use and exploit PATENT RIGHTS and/or JOINT PATENT
RIGHTS and/or TECHNOLOGICAL INFORMATION or (b) the lowest royalty which is
within the "Competitive" range as hereinafter defined, at the time GENERAL's
license to CEREBROTEC is terminated. A royalty rate shall be regarded as
"Competitive" if it is within the range of royalty rates that GENERAL would
charge in an arms length transaction with a licensee which was not and had not
been a sponsor of research at GENERAL, taking into account the value of the
licensed technology at the time GENERAL's license to CEREBROTEC is terminated;

                  (e)      the SUBLICENSEE agrees to be bound by the due
diligence obligations of CEREBROTEC pursuant to paragraph 3.1 hereof (whether
set by the parties or by Alternate Dispute Resolution pursuant to Section 10.9)
in the field and territory of the sublicense;

                  (f)      GENERAL has the right to terminate such sublicense
upon fifteen (15) days' prior written notice to CEREBROTEC and such SUBLICENSEE
in the event of any material breach of the obligation to make the payments
described in clause (iv) of this paragraph 9.3, unless such breach is cured
prior to the expiration of such fifteen (15) day period, and shall further have
the right to terminate such sublicense in the event of SUBLICENSEE's failure to
meet its due diligence obligations pursuant to clause (v) hereof;

                  (g)      GENERAL shall not assume, and shall not be
responsible to such SUBLICENSEE for, any representations, warranties or
obligations of CEREBROTEC to such SUBLICENSEE, other than to permit such
SUBLICENSEE to exercise any rights to PATENT RIGHTS and JOINT PATENT RIGHTS and
TECHNOLOGICAL INFORMATION that are granted under such sublicense agreement
consistent with the terms of this AGREEMENT.

         9.4 Upon termination of any license granted hereunder CEREBROTEC shall
pay GENERAL all royalties due or accrued on (i) the sale of PRODUCT up to and
including the date of termination and (ii) for twelve (12) months following the
date of termination, the sale of PRODUCT manufactured prior to the termination
date.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                               10. MISCELLANEOUS

         10.1     This Agreement constitutes the entire understanding between
the parties with respect to the subject matter hereof.

         10.2     In order to facilitate implementation of this Agreement,
GENERAL and CEREBROTEC are designating the following individuals to act on their
behalf with respect to this Agreement for the matter indicated below:

                  (a)      with respect to all royalty payments, any
correspondence pertaining to any PATENT RIGHT, or any notice of the use of
GENERAL's name, for GENERAL, the Director, Corporate Sponsored Research and
Licensing, and for CEREBROTEC, Seth P. Finklestein, M.D., President, Cerebrotec,
Inc., 308A Hunnewell St., Needham, MA 02494; provided that correspondence
relating to the billing of patent costs shall be copied to, for GENERAL, the
Business Manager, Corporate Sponsored Research and Licensing.

                  (b)      any amendment of or waiver under this Agreement, any
written notice including progress reports or other communication pertaining to
the Agreement: for GENERAL, the Director, Corporate Sponsored Research and
Licensing; and for CEREBROTEC, Seth P. Finklestein, M.D., President, Cerebrotec,
Inc., 308A Hunnewell St., Needham, MA 02494.

                  (c)      the above designations may be superseded from time to
time by alternative designations made by: for GENERAL, the Vice President for
Corporate Sponsored Research and Licensing and for CEREBROTEC, Seth P.
Finklestein, M.D., President, Cerebrotec, Inc., 308A Hunnewell St., Needham, MA
02494.

         10.3     This Agreement may be amended and any of its terms or
conditions may be waived only by a written instrument executed by the parties
or, in the case of a waiver, by the party waiving compliance. The failure of
either party at any time or times to require performance of any provision hereof
shall in no manner affect its rights at a later time to enforce the same. No
waiver by either party of any condition shall be deemed as a further or
continuing waiver of such condition or term or of any other condition or term.

         10.4     This Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors and
permitted assigns.

         10.5     Any delays in or failures of performance by either party under
this Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the party
affected, including but not limited to: Acts of God; acts, regulations or laws
of any government; strikes or their concerted acts of worker; fires; floods,
explosions; riots; wars; rebellion; and sabotage. Any time for performance
hereunder shall be extended by the actual time of delay caused by such
occurrence.

         10.6     Neither party shall use the name of the other party or CMCC or
of any staff member, officer, employee or student of the other party or CMCC or
any adaptation thereof in any advertising, promotional, or sales literature,
publicity or in any document employed to obtain

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
funds or financing without the prior written approval of the party or individual
whose name is to be used. For GENERAL, such approval shall be obtained from the
Director of Public Affairs.

         10.7     This Agreement shall be governed by and construed and
interpreted in accordance with the laws of the Commonwealth of Massachusetts.

         10.8     This Agreement shall not be assignable by GENERAL without
CEREBROTEC's written consent except for the right to receive royalties or other
payments payable herein. CEREBROTEC may at its own discretion and without
approval by GENERAL transfer its interest or any part thereof under this
Agreement to a wholly-owned subsidiary or, in the event of the merger,
consolidation or sale of substantially all of CEREBROTEC's assets or that
portion of CEREBROTEC's business to which this Agreement relates, to the
purchaser or assignee of said assets or to the surviving entity in any merger,
consolidation or acquisition. In the event of any such transfer, the transferee
shall assume and be bound by the provisions of this Agreement. Otherwise this
Agreement shall be assignable by CEREBROTEC only with the consent in writing of
GENERAL.

         10.9     For any and all claims, disputes, or controversies arising
under, out of, or in connection with this Agreement, except issues relating to
the validity, construction or effect of any PATENT RIGHT, which the parties
shall be unable to resolve within sixty (60) days, the party raising such
dispute shall promptly advise the other party of such claim, dispute, or
controversy in a writing which describes in reasonable detail the nature of such
dispute. By not later than five (5) business days after the recipient has
received such notice of dispute, each party shall have selected for itself a
representative who shall have the authority to bind such party and shall
additionally have advised the other party in writing of the name and title of
such representative. By not later than ten (10) business days after the date of
such notice of dispute, such representatives shall agree upon a third party
which is in the business of providing Alternative Dispute Resolution (ADR)
services (hereinafter, "ADR Provider") and shall schedule a date with such ADR
Provider to engage in ADR. Thereafter, the representatives of the parties shall
engage in good faith in an ADR process under the auspices of the selected ADR
Provider. If within the aforesaid thirty (30) business days after the date of
the notice of dispute the representatives of the parties have not been able to
agree upon an ADR Provider and schedule a date to engage in ADR, or if they have
not been able to resolve the dispute within thirty (30) business days after the
termination of ADR, the parties shall have the right to pursue any other
remedies legally available to resolve such dispute in either the Courts of the
Commonwealth of Massachusetts or in the United States District Court for the
District of Massachusetts, to whose jurisdiction for such purposes GENERAL and
CEREBROTEC hereby irrevocably consents and submits. Notwithstanding the
foregoing, nothing in this Paragraph 10.9 shall be construed to waiver any
rights or timely performance of any obligations existing under this Agreement.

         10.10    If any provision(s) of this Agreement are or become invalid,
are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect
during the term hereof, it is the intention of the parties that the remainder of
this agreement shall not be effected thereby. It is further the intention of the
parties that in lieu of each such provision which is invalid, illegal or
unenforceable, there are substituted or added as part of this Agreement a
provision which shall be as similar as possible in economic

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
and business objectives as intended by the parties to such invalid, illegal or
enforceable provision, but shall be valid, legal and enforceable.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         THE PARTIES have duly executed this Agreement as of the date first
shown above written.

<TABLE>
<CAPTION>
CEREBROTEC, INC.                                           THE GENERAL HOSPITAL CORPORATION
<S>                                                        <C>
BY: Signature on File                                      BY: /s/ David Glass, Ph.D.

TITLE:  President                                          TITLE:  Assoc. Dir., Office. of Corp Sponsored
                                                           Research and Licensing

DATE:  2/5/01                                              DATE:  2/5/01
</TABLE>

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX A
                                 PATENT RIGHTS

U.S. and foreign patent applications corresponding to the following inventions
and U.S. patent applications:

                                       [*]

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]